Nasogen (Xylometazoline Hydrochloride)

Xylometazoline Hydrochloride selectively stimulates alpha‑adrenergic receptors on the blood vessels of the nasal mucosa, causing vasoconstriction. This reduces swelling and opens the nasal passages, providing rapid relief of congestion.

The appropriate dose and frequency are determined by a healthcare professional based on the patient’s age, condition, and response. Users should follow the prescriber’s instructions and the product label.

Safety data for Xylometazoline Hydrochloride in pregnancy and lactation are limited. Women who are pregnant, planning pregnancy, or breastfeeding should consult their healthcare provider before using Nasogen.

To request Nasogen, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nasogen’s active ingredient, Xylometazoline, is an alpha‑adrenergic agonist similar to phenylephrine or oxymetazoline. All provide short‑term relief, but Xylometazoline has a rapid onset and is often preferred for its efficacy in both viral and allergic congestion. Choice depends on individual response and physician recommendation.

Store Nasogen at room temperature, below 25 °C. Keep the bottle tightly closed in its original packaging, protect it from moisture and direct sunlight, and avoid freezing.

Nasogen is applied intranasally as a spray. The patient tilts the head slightly forward, inserts the nozzle into one nostril, and sprays the recommended number of sprays while breathing in gently. The process is repeated in the other nostril if directed.

Serious risks include rebound nasal congestion if used longer than recommended, severe hypertension, cardiac arrhythmias, nasal ulceration or septal perforation, and allergic reactions such as rash or swelling. Any of these symptoms require immediate medical attention.

Nasogen should be avoided by individuals with known hypersensitivity to Xylometazoline or any formulation ingredients, patients with severe hypertension, coronary artery disease, or uncontrolled cardiovascular conditions, and children under the age specified on the label unless advised by a clinician.